Delve into the efficacy and safety data for the antibody–drug conjugates currently approved by the US FDA across tumor types such as hematologic, genitourinary, and gynecologic cancers.
A thorough understanding of the relationship between viruses and hematologic cancers can help clinicians to deliver precise therapies and monitor potential complications.
Many more targeted therapies are now available for people with AML, in both the newly diagnosed and relapsed/refractory settings. Learn about the genetic and protein targets, and their associated therapeutics, in this review.
How do nutrition, supplements and antibiotics impact patient outcomes?
Recent research suggests that the gut microbiome could be an important modulator of response to CAR T-cell therapy in patients with hematologic cancers.
Prof. Marion Subklewe takes us through the latest evidence, highlighting the impact of antibiotics, nutrition, and dietary supplements, and discusses how to devise interventions to improve patient outcomes.
A patient receiving arsenic trioxide for acute promyelocytic leukemia developed drug-induced acute pericarditis that was successfully treated with colchicine.
A case series of three patients suggests that obinutuzumab-induced acute thrombocytopenia is a frequent, possibly non-relapsing, and unique adverse event that deserves more attention than it currently receives.
Live: Monday 10 June 2024, from 16:30 – 18:00 (CEST)
In this live interactive webinar, a multidisciplinary team of speakers will provide practical guidance on managing patients with cutaneous T-cell lymphoma. Learn about the key aspects of diagnosis and treatment via a series of patient cases.
Diffuse large B-cell lymphoma (DLBCL) is a curable disease with variable outcomes due to underlying heterogeneous clinical and molecular features—features that are insufficiently characterized with our current tools. Due to these limitations …
Cancer is one of the primary public health problems worldwide [ 1 ]. In 2022 it is estimated 19.3 million new cancer cases and 10 million deaths, indicating a significant global burden [ 2 ]. Oncological research is focused in finding new and …
The frequency of antibodies to Ku varies in various autoimmune diseases. In 2019, Spielmann et al. identified two types of anti-Ku syndrome based on a hierarchical clustering analysis. Sjögren’s syndrome occurs both in the first type of anti-Ku …
Myelodysplastic syndromes/neoplasms (MDS) comprise a group of heterogenous pathologically distinct diseases with varied prognosis and natural risk of leukemia progression [ 1 , 2 ]. MDS pathogenesis begins from different genetic alterations …
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.
A series of patient cases underpin this live interactive webinar that aims to provide practical guidance on a multidisciplinary approach to managing patients with cutaneous T-cell lymphoma.
Take on interactive case studies with a focus on hematology. Each case has been prepared by renowned experts in the field and features knowledge-check questions with answers to help keep you and your practice up to date.
Chimeric antigen receptor T cell (CAR-T) therapies targeting the CD19 antigen have been associated with high and durable response rates in patients with diffuse large B cell lymphoma (DLBCL). CAR-T cell therapies are commonly administered in the …
Blinatumomab is efficacious in patients with B-cell acute lymphoblastic leukemia (B-ALL), yet limited real-world data exists in this context. This retrospective study provided real-world data on the treatment pattern, effectiveness, and safety of …
Despite chimeric antigen receptor (CAR) T-cell therapy has achieved great advances in recent year, approximately 50% of relapsed/refractory B cell acute lymphoblastic leukemia (r/r B-ALL) patients treated with CAR-T experience relapse 6 months …
A 66-year-old woman with rheumatoid arthritis (RA) who had been receiving methotrexate (MTX) for 2 years presented with tarry stools. Contrast-enhanced computed tomography (CT) of the abdomen revealed irregular wall thickening in the ileocecal …
Delve into the efficacy and safety data for the antibody–drug conjugates currently approved by the US FDA across tumor types such as hematologic, genitourinary, and gynecologic cancers.
Mezigdomide has shown promising antitumor activity in combination with dexamethasone in a phase 1/2 trial comprising patients with relapsed and refractory multiple myeloma.
